Ads
related to: biogen'sreviewscout.org has been visited by 100K+ users in the past month
Search results
European Commission approves Biogen’s QALSODY for ALS treatment
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe European Commission (EC) has granted marketing authorisation for Biogen's QALSODY (tofersen) an...
European Commission grants marketing approval to Biogen's ALS drug
Reuters via Yahoo News· 5 days agoThe approval is based on a 108-patient trial that showed Qalsody reduced levels of a neurofilament...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a...
Morningstar· 5 days agoGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors Glancy Prongay & Murray LLP (“GPM ...
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Guru Focus· 2 days agoLong-established in the Drug Manufacturers industry, Biogen Inc (BIIB, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth, and valuation ...
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Benzinga via Yahoo Finance· 5 days agoOn Thursday, the European Commission granted marketing authorization under exceptional circumstances...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) ...
BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law...
Benzinga· 4 days agoNEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (NASDAQ:BIIB) Securities Class Action Lawsuit. If you
RBC maintains $317 price target on Biogen stock, cites Skyclarys importance By Investing.com
Investing.com· 7 days agoThe firm's analysis addressed concerns regarding Skyclarys, a key drug in Biogen's portfolio. The...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 1 day agoThe law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District ...
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Zacks via Yahoo Finance· 5 days agoBiogen’s stock was up 2.6% on Thursday in response to Qalsody’s approval in the EU. Biogen’s stock...